IP Library Granted Patent US 8,580,956
Granted Patent B2
US 8,580,956 · App. 12/600,910 · Granted Nov 12, 2013

Gamma secretase modulators

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,580,956
App. No.
12/600,910
Granted
Nov 12, 2013
Kind
B2
Abstract

In its many embodiments, the present invention provides a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.

Claims (17)

1. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein

U is N or —CH;

R 1 is hydrogen, alkyl, alkenyl, or alkoxy;

R 2 and R 6 are joined together to form 1) a 5-7 membered cycloalkyl ring, optionally substituted with —OH, or 2) a heterocyclyl ring optionally fused with an aryl ring;

R 7 is a 1) hydrogen, 2) an alkyl, or 3) a phenyl ring optionally substituted with 1-3 halo; and

R 8 is hydrogen, alkyl, alkenyl, or alkoxy.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein U is N.

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein U is —CH.

4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the halo is fluoro.

5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 8 are hydrogen.

6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the cycloalkyl ring formed by R 2 and R 6 is a cyclopentyl ring or cyclohexyl ring.

7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 and R 6 join together to form a heterocyclyl ring.

8. The compound according to claim 7 or a pharmaceutically acceptable salt thereof, wherein the heterocyclyl ring is selected from pyrrolidinyl, piperidinyl, pyridazinyl, piperazinyl, morpholinyl, isoxazolidinyl, tetrahydrofuranyl and tetrahydropyranyl.

9. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

10. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

11. A pharmaceutical composition comprising a compound according to claim 5 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →